Neuronetics, Inc. (STIM) 8-K Current Report: March 17, 2026
Filed: March 17, 2026
Health Care
Surgical & Medical Instruments & ApparatusNeuronetics, Inc. (STIM) 8-K current report filed with SEC EDGAR on March 17, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items3 items
- Item 2.02: Results of Operations and Financial Condition
- Item 5.02: Departure/Election of Directors or Officers
- Item 7.01: Regulation FD Disclosure
Neuronetics, Inc. 8-K Mar 17, 2026 Event Analysis
Item 2.02 · Results of Operations and Financial Condition
- • Q4 and full-year 2025 earnings released March 17, 2026 — covering period ended December 31, 2025
- • Full financial details in Exhibit 99.1 press release; key figures not disclosed in this filing item
Item 5.02 · Departure/Election of Directors or Officers
- • New CEO Daniel Reuvers starts March 23, 2026; age 63 with 35+ years medtech experience including CEO of Tactile Medical (TCMD) 2020–2024
- • Base salary $730,000 with target annual bonus at 100% of base salary (~$730,000 target total cash)
- • Equity grant of 1,500,000 RSUs vesting equally over 3 years (500,000 units/year) — significant retention incentive
- • Severance package includes 12 months base salary + prorated target bonus if terminated without cause or for good reason
- • Prior track record includes leading Integra's $1B Codman neurosurgical segment; two successful private company exits — suggests operational credibility in medtech
Item 7.01 · Regulation FD Disclosure
- • Forward-looking statements cover revenue, expenses, growth outlook for upcoming quarters and full-year fiscal 2026
- • Key risk flags: reliance on NeuroStar system for all revenue, history of losses, ability to maintain positive cash flow
- • Credit facility terms and self-sustainability of existing cash balances cited as specific financial risks
- • Greenbrook TMS integration risk highlighted — potential effects on business relationships and operating results
- • Better Me Provider Program rollout timeline flagged as execution risk worth monitoring for commercial traction signals
Other Neuronetics, Inc. 8-K Filings
Get deeper insights on Neuronetics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.